1. India Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
Arvee Laboratories (India) Ltd.

Arvee Laboratories (India) Ltd.

NNSE:ARVEE
197.38
INR
-5.52
(-2.72%)
3.75EPS
44.11P/E
1.82BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
14.52
15.96
33.01
41.91
55.05
48.96
40.69
55.31
36.02
55.6
27.53
34.88
28.53
38.23
Basic EPS, GAAP
0.02
-2.03
0.23
1.91
1.29
2.05
2.09
3.14
2.34
3.74
0.95
1.95
2.29
3.75
Free Cash Flow per Basic Share
-8.11
3.6
1.98
3.08
5.55
7.22
7.28
-0.68
-1.53
1.31
0.98
-1.87
-2.68
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.78
1.28
2.4
3.81
12.88
14.94
17.02
19.45
21.73
25.46
26.42
28.37
30.66
- -
Tangible Book Value per Share
2.78
1.28
2.4
3.81
12.88
14.9
16.99
19.43
21.71
25.46
26.42
28.37
30.66
- -
Basic Weighted Avg Shares
8
8
8
8
8
11
11
9
11
11
11
11
11
11
Sales/Revenue/Turnover
118
130
268
341
464
540
448
471
397
613
303
384
314
413
Operating Margin (%)
13.76
10.63
13.13
11.33
10.89
7.21
8.56
8.08
7.56
8.55
4.9
6.41
6.29
9.96
Depreciation Expense
2
7
15
21
22
24
24
25
24
21
15
12
12
12
Net Income, GAAP
- -
-16
2
16
11
23
23
27
26
41
11
21
25
41
Effective Tax Rate (%)
18.97
- -
65.02
- -
43.15
11.05
25.61
26.48
25.38
33.19
42.51
25.2
- -
10.86
Profit Margin (%)
0.16
-12.7
0.7
4.56
2.35
4.19
5.13
5.68
6.48
6.72
3.47
5.59
8.04
9.82
Working Capital
15
28
34
39
60
48
54
73
89
127
99
158
178
- -
LT Debt
80
153
174
166
79
35
20
10
10
10
10
10
11
- -
Total Equity
31
14
26
42
142
165
188
214
239
281
291
313
338
- -
Return on Invested Capital (%)
11.05
- -
4.91
- -
9.58
11.4
10.66
10.06
7.91
12.34
2.91
5.9
- -
- -
Return on Capital (%)
7.98
- -
4.99
- -
9.3
11.87
11.4
11.48
9.79
15.36
3.92
7.24
- -
- -
Return on Common Equity (%)
1.19
-73.58
9.24
45.34
11.84
14.76
13.05
13.32
11.34
15.84
3.68
7.11
7.77
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
11
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
2,351
1,475
1,824

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
248
- -
Cash, Cash Equivalents & STI
- -
33
- -
Accounts Receivable, Net
- -
105
- -
Inventories
- -
92
- -
Total Current Liabilities
- -
70
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
38.92%
9.62%
8.08%
Free Cash Flow
-16.27%
-53.79%
43.35%
Net Income, GAAP
92.76%
20.7%
17.65%
Sales/Revenue/Turnover
6.43%
-0.69%
-18.21%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
106
125
89
65
384
2026
75
35
98
108
314
2027
172
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.85
0.89
0.14
0.06
1.95
2026
0.15
0.01
1.66
0.47
2.29
2027
1.54
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Shalin Sudhakarbhai Patel
Full Time Employees
57
Sector
Process industries
Industry
Chemicals: specialty
Address
403, Entice Building Ahmedabad GU India 380058
IPO Date
Feb 22, 2018
Website
arveelabs.com
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
PI Industries Limited (NSE:PIIND)
Business
Arvee Laboratories (India) Ltd. Arvee Laboratories (India) Ltd. manufactures and sells specialized chemicals primarily in the specialty chemicals sector, focusing on polymer modifiers, contrast media intermediates, and drug intermediates for industrial, pharmaceutical, and medical imaging applications. The company produces polymer modifiers including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(β-hydroxyethyl)-isophthalate; contrast media intermediates such as 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, dimethyl 5-aminoisophthalate, 3,5-dinitrobenzoic acid, and 3,5-diamino benzoic acid; and drug intermediates comprising 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4-amino pyridine, and 2-chloro-5-nitrobenzoic acid. Incorporated in 2012 and headquartered at 403, Entice Building, Ahmedabad, Gujarat, India, Arvee Laboratories (India) Ltd. operates with approximately 65 employees and exports its products internationally to markets including pharmaceutical manufacturers in India, the United States, and Europe. Recent developments include the appointment of Saurin Gandhi as additional director and chief financial officer effective August 12, 2025; the resignation of whole-time director Shalin Bharatbhai Chokshi effective June 30, 2025; approval of Q1 FY26 results and scheduling of the 13th annual general meeting for September 24, 2025; and submission of the annual report for FY2024-25.